Rasheed AA, Barwad A, Dhamija E, Garg R, Pandey R, Shamim SA, Arun Raj ST, Rastogi S. Advanced dermatofibrosarcoma protuberans: an updated analysis of cases from an Indian sarcoma clinic.
Future Sci OA 2021;
7:FSO743. [PMID:
34737884 PMCID:
PMC8558865 DOI:
10.2144/fsoa-2020-0198]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 06/14/2021] [Indexed: 02/07/2023] Open
Abstract
AIM
Dermatofibrosarcoma protuberans (DFSP) accounts for less than 2% of all soft-tissue sarcomas.
PATIENTS & METHODS
We retrospectively reviewed our database for patients with locally advanced or metastatic DFSP who had presented to our clinic between January 2016 and January 2020.
RESULTS
We identified a total of 14 patients, of whom ten had sarcomatous transformation. Eleven cases had metastatic disease and three were locally advanced. The initial partial response rate to first-line imatinib was 76.9% and the overall median progression-free survival on imatinib was 15 months.
CONCLUSION
We had a high proportion of patients with sarcomatous transformation, in contrast to their relative rarity in the West. While most patients had initial good responses to imatinib, second-line therapies were not as effective.
Collapse